Remaking Medicine™
EQRx was a biopharmaceutical company founded in 2019 committed to developing innovative, patent-protected medicines and delivering them at dramatically lower prices than traditional pharmaceutical companies. The company built a pipeline of 10+ programs including Phase 3 oncology assets for non-small cell lung cancer, raised over $750 million in funding, and was acquired by Revolution Medicines in November 2023.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2021
Jan 2020
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
